Annual Operating Profit
-$171.75 M
-$70.99 M-70.45%
December 31, 2023
Summary
- As of February 7, 2025, LXRX annual operating income is -$171.75 million, with the most recent change of -$70.99 million (-70.45%) on December 31, 2023.
- During the last 3 years, LXRX annual operating profit has risen by +$7.04 million (+3.93%).
- LXRX annual operating profit is now -200.98% below its all-time high of $170.08 million, reached on December 31, 2019.
Performance
LXRX Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Profit
-$63.69 M
-$8.34 M-15.06%
September 30, 2024
Summary
- As of February 7, 2025, LXRX quarterly operating income is -$63.69 million, with the most recent change of -$8.34 million (-15.06%) on September 30, 2024.
- Over the past year, LXRX quarterly operating profit has dropped by -$18.36 million (-40.50%).
- LXRX quarterly operating profit is now -125.14% below its all-time high of $253.31 million, reached on September 30, 2019.
Performance
LXRX Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Operating Profit
-$211.12 M
-$14.06 M-7.14%
September 30, 2024
Summary
- As of February 7, 2025, LXRX TTM operating income is -$211.12 million, with the most recent change of -$14.06 million (-7.14%) on September 30, 2024.
- Over the past year, LXRX TTM operating profit has dropped by -$25.18 million (-13.54%).
- LXRX TTM operating profit is now -203.02% below its all-time high of $204.93 million, reached on September 30, 2019.
Performance
LXRX TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Profit Formula
Operating Profit = Gross Profit − Operating Expenses
LXRX Operating Profit Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -70.5% | -40.5% | -13.5% |
3 y3 years | +3.9% | -175.8% | -120.3% |
5 y5 years | -66.3% | -125.1% | -224.1% |
LXRX Operating Profit Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -97.2% | at low | -175.8% | at low | -142.4% | at low |
5 y | 5-year | -201.0% | +3.9% | -781.6% | at low | -224.1% | +3.5% |
alltime | all time | -201.0% | +3.9% | -125.1% | at low | -203.0% | +3.5% |
Lexicon Pharmaceuticals Operating Profit History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$63.69 M(+15.1%) | -$211.12 M(+7.1%) |
Jun 2024 | - | -$55.35 M(+22.1%) | -$197.06 M(+6.0%) |
Mar 2024 | - | -$45.33 M(-3.0%) | -$185.94 M(+8.3%) |
Dec 2023 | -$171.75 M(+70.5%) | -$46.74 M(-5.8%) | -$171.75 M(+10.6%) |
Sep 2023 | - | -$49.63 M(+12.2%) | -$155.29 M(+20.6%) |
Jun 2023 | - | -$44.24 M(+42.1%) | -$128.75 M(+18.6%) |
Mar 2023 | - | -$31.14 M(+2.9%) | -$108.52 M(+7.7%) |
Dec 2022 | -$100.76 M(+15.7%) | -$30.28 M(+31.1%) | -$100.76 M(+5.2%) |
Sep 2022 | - | -$23.09 M(-3.8%) | -$95.81 M(+0.1%) |
Jun 2022 | - | -$24.01 M(+2.7%) | -$95.68 M(+6.7%) |
Mar 2022 | - | -$23.38 M(-7.7%) | -$89.63 M(+2.9%) |
Dec 2021 | -$87.09 M(-51.3%) | -$25.33 M(+10.3%) | -$87.09 M(+26.2%) |
Sep 2021 | - | -$22.96 M(+27.9%) | -$68.98 M(-25.2%) |
Jun 2021 | - | -$17.96 M(-13.8%) | -$92.17 M(-32.8%) |
Mar 2021 | - | -$20.84 M(+188.4%) | -$137.19 M(-23.3%) |
Dec 2020 | -$178.78 M(-205.1%) | -$7.22 M(-84.3%) | -$178.78 M(-18.3%) |
Sep 2020 | - | -$46.14 M(-26.7%) | -$218.78 M(-371.2%) |
Jun 2020 | - | -$62.98 M(+0.9%) | $80.68 M(-35.5%) |
Mar 2020 | - | -$62.44 M(+32.2%) | $125.11 M(-26.4%) |
Dec 2019 | $170.08 M(-264.7%) | -$47.22 M(-118.6%) | $170.08 M(-17.0%) |
Sep 2019 | - | $253.31 M(-1465.9%) | $204.93 M(-387.4%) |
Jun 2019 | - | -$18.55 M(+6.2%) | -$71.31 M(-14.1%) |
Mar 2019 | - | -$17.47 M(+41.2%) | -$83.04 M(-19.6%) |
Dec 2018 | -$103.28 M(-19.6%) | -$12.37 M(-46.1%) | -$103.28 M(-10.7%) |
Sep 2018 | - | -$22.93 M(-24.3%) | -$115.64 M(-5.4%) |
Jun 2018 | - | -$30.27 M(-19.7%) | -$122.23 M(-2.9%) |
Mar 2018 | - | -$37.71 M(+52.5%) | -$125.85 M(-2.1%) |
Dec 2017 | -$128.52 M(+0.5%) | -$24.73 M(-16.2%) | -$128.52 M(+2.7%) |
Sep 2017 | - | -$29.52 M(-12.9%) | -$125.14 M(-5.7%) |
Jun 2017 | - | -$33.89 M(-16.1%) | -$132.70 M(-2.0%) |
Mar 2017 | - | -$40.38 M(+89.2%) | -$135.35 M(+5.8%) |
Dec 2016 | -$127.87 M(-1263.3%) | -$21.35 M(-42.4%) | -$127.87 M(+692.4%) |
Sep 2016 | - | -$37.08 M(+1.5%) | -$16.14 M(+131.1%) |
Jun 2016 | - | -$36.54 M(+11.1%) | -$6.98 M(-344.2%) |
Mar 2016 | - | -$32.91 M(-136.4%) | $2.86 M(-74.0%) |
Dec 2015 | $10.99 M(-112.8%) | $90.39 M(-423.7%) | $10.99 M(-113.4%) |
Sep 2015 | - | -$27.92 M(+4.6%) | -$81.94 M(-0.5%) |
Jun 2015 | - | -$26.70 M(+7.8%) | -$82.32 M(+1.3%) |
Mar 2015 | - | -$24.77 M(+876.5%) | -$81.28 M(-5.3%) |
Dec 2014 | -$85.84 M(-17.9%) | -$2.54 M(-91.0%) | -$85.84 M(-18.7%) |
Sep 2014 | - | -$28.31 M(+10.3%) | -$105.56 M(-1.5%) |
Jun 2014 | - | -$25.66 M(-12.5%) | -$107.14 M(-2.3%) |
Mar 2014 | - | -$29.33 M(+31.7%) | -$109.62 M(+4.8%) |
Dec 2013 | -$104.58 M(+6.1%) | -$22.27 M(-25.5%) | -$104.58 M(-2.3%) |
Sep 2013 | - | -$29.88 M(+6.1%) | -$107.01 M(+6.6%) |
Jun 2013 | - | -$28.15 M(+15.9%) | -$100.35 M(+5.1%) |
Mar 2013 | - | -$24.29 M(-1.6%) | -$95.52 M(-3.1%) |
Dec 2012 | -$98.53 M | -$24.69 M(+6.4%) | -$98.53 M(-1.9%) |
Sep 2012 | - | -$23.22 M(-0.4%) | -$100.41 M(-2.4%) |
Jun 2012 | - | -$23.32 M(-14.6%) | -$102.89 M(-2.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2012 | - | -$27.30 M(+2.7%) | -$105.50 M(-1.7%) |
Dec 2011 | -$107.33 M(+15.4%) | -$26.58 M(+3.4%) | -$107.33 M(+6.8%) |
Sep 2011 | - | -$25.69 M(-0.9%) | -$100.47 M(+1.5%) |
Jun 2011 | - | -$25.93 M(-11.0%) | -$99.03 M(+1.9%) |
Mar 2011 | - | -$29.14 M(+47.8%) | -$97.18 M(+4.5%) |
Dec 2010 | -$93.01 M(+3.4%) | -$19.71 M(-18.7%) | -$93.01 M(-2.2%) |
Sep 2010 | - | -$24.25 M(+0.7%) | -$95.14 M(+2.7%) |
Jun 2010 | - | -$24.07 M(-3.6%) | -$92.64 M(+1.4%) |
Mar 2010 | - | -$24.97 M(+14.3%) | -$91.35 M(+1.6%) |
Dec 2009 | -$89.96 M(-6.8%) | -$21.85 M(+0.4%) | -$89.96 M(+1.1%) |
Sep 2009 | - | -$21.76 M(-4.5%) | -$89.00 M(-3.3%) |
Jun 2009 | - | -$22.78 M(-3.3%) | -$92.06 M(-3.8%) |
Mar 2009 | - | -$23.57 M(+12.8%) | -$95.67 M(-0.9%) |
Dec 2008 | -$96.53 M(+28.8%) | -$20.89 M(-15.8%) | -$96.53 M(+2.6%) |
Sep 2008 | - | -$24.82 M(-5.9%) | -$94.11 M(+6.1%) |
Jun 2008 | - | -$26.39 M(+8.0%) | -$88.73 M(+10.5%) |
Mar 2008 | - | -$24.44 M(+32.3%) | -$80.30 M(+7.1%) |
Dec 2007 | -$74.95 M(+35.7%) | -$18.47 M(-5.0%) | -$74.95 M(+5.5%) |
Sep 2007 | - | -$19.44 M(+8.3%) | -$71.06 M(+10.5%) |
Jun 2007 | - | -$17.95 M(-6.0%) | -$64.32 M(+1.6%) |
Mar 2007 | - | -$19.09 M(+31.0%) | -$63.31 M(+14.6%) |
Dec 2006 | -$55.23 M(+52.9%) | -$14.57 M(+14.7%) | -$55.23 M(+58.1%) |
Sep 2006 | - | -$12.71 M(-25.0%) | -$34.94 M(-3.7%) |
Jun 2006 | - | -$16.93 M(+53.7%) | -$36.29 M(+7.1%) |
Mar 2006 | - | -$11.02 M(-292.6%) | -$33.87 M(-6.2%) |
Dec 2005 | -$36.12 M(-23.9%) | $5.72 M(-140.7%) | -$36.12 M(-16.6%) |
Sep 2005 | - | -$14.05 M(-3.2%) | -$43.30 M(+0.2%) |
Jun 2005 | - | -$14.52 M(+9.4%) | -$43.19 M(-4.3%) |
Mar 2005 | - | -$13.27 M(+809.9%) | -$45.12 M(-4.9%) |
Dec 2004 | -$47.45 M(-24.2%) | -$1.46 M(-89.5%) | -$47.45 M(-18.7%) |
Sep 2004 | - | -$13.95 M(-15.2%) | -$58.34 M(-1.6%) |
Jun 2004 | - | -$16.44 M(+5.4%) | -$59.26 M(-2.3%) |
Mar 2004 | - | -$15.60 M(+26.4%) | -$60.66 M(-3.1%) |
Dec 2003 | -$62.59 M(-0.5%) | -$12.34 M(-17.0%) | -$62.59 M(-3.5%) |
Sep 2003 | - | -$14.87 M(-16.7%) | -$64.84 M(-3.9%) |
Jun 2003 | - | -$17.85 M(+1.8%) | -$67.46 M(+3.4%) |
Mar 2003 | - | -$17.53 M(+20.2%) | -$65.25 M(+3.7%) |
Dec 2002 | -$62.89 M(+44.1%) | -$14.59 M(-16.6%) | -$62.89 M(+3.2%) |
Sep 2002 | - | -$17.49 M(+11.8%) | -$60.93 M(+18.6%) |
Jun 2002 | - | -$15.64 M(+3.1%) | -$51.40 M(+7.1%) |
Mar 2002 | - | -$15.18 M(+20.2%) | -$47.99 M(+10.0%) |
Dec 2001 | -$43.64 M(+23.0%) | -$12.63 M(+58.7%) | -$43.64 M(+4.3%) |
Sep 2001 | - | -$7.95 M(-35.0%) | -$41.85 M(+7.9%) |
Jun 2001 | - | -$12.24 M(+13.1%) | -$38.79 M(+18.0%) |
Mar 2001 | - | -$10.82 M(-0.2%) | -$32.86 M(-7.4%) |
Dec 2000 | -$35.48 M(+177.2%) | -$10.84 M(+121.7%) | -$35.48 M(+44.0%) |
Sep 2000 | - | -$4.89 M(-22.5%) | -$24.64 M(+24.8%) |
Jun 2000 | - | -$6.31 M(-53.0%) | -$19.75 M(+47.0%) |
Mar 2000 | - | -$13.44 M | -$13.44 M |
Dec 1999 | -$12.80 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual operating income?
- What is the all time high annual operating profit for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual operating profit year-on-year change?
- What is Lexicon Pharmaceuticals quarterly operating income?
- What is the all time high quarterly operating profit for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly operating profit year-on-year change?
- What is Lexicon Pharmaceuticals TTM operating income?
- What is the all time high TTM operating profit for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM operating profit year-on-year change?
What is Lexicon Pharmaceuticals annual operating income?
The current annual operating profit of LXRX is -$171.75 M
What is the all time high annual operating profit for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual operating income is $170.08 M
What is Lexicon Pharmaceuticals annual operating profit year-on-year change?
Over the past year, LXRX annual operating income has changed by -$70.99 M (-70.45%)
What is Lexicon Pharmaceuticals quarterly operating income?
The current quarterly operating profit of LXRX is -$63.69 M
What is the all time high quarterly operating profit for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly operating income is $253.31 M
What is Lexicon Pharmaceuticals quarterly operating profit year-on-year change?
Over the past year, LXRX quarterly operating income has changed by -$18.36 M (-40.50%)
What is Lexicon Pharmaceuticals TTM operating income?
The current TTM operating profit of LXRX is -$211.12 M
What is the all time high TTM operating profit for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM operating income is $204.93 M
What is Lexicon Pharmaceuticals TTM operating profit year-on-year change?
Over the past year, LXRX TTM operating income has changed by -$25.18 M (-13.54%)